Big Flats, NY, March 2, 2015 – X-GEN Pharmaceuticals announces availability of Magnesium Sulfate Injection, USP. Healthcare systems around the U.S are experiencing a shortage of Magnesium Sulfate, which is a critical component in Total Parenteral Nutrition (TPN), supplying vital nutrients to patients who need IV nutrition to stay alive. It also is indicated as an anticonvulsant to prevent and control seizures in pre-eclampsia and eclampsia, respectively during pregnancy.
Due to the on-going supply concerns for this important drug, the Center for Drug Evaluation & Research (CDER) has approved under “expedited review” the ANDA filed by Exela Pharma Sciences, our development and manufacturing partner. The timely addition of such a key treatment to X-GEN’s product portfolio speaks to our on-going commitment for improving healthcare as well as our ability to react to market demands by utilizing our strengths in supply chain management.
X-GEN Corporate Vice President Rob Liles added, “X-GEN’s close relationships through the entire supply chain ensure we remain flexible and able to respond quickly to the needs of the healthcare community. Our broad network of alliances allows X-GEN to come to market quickly with medications that are in short supply and are critical to the health of many patients.”
X-GEN Pharmaceuticals, Inc. is focused on the development, manufacture and delivery of specialty pharmaceutical products which serve the healthcare community as effective, generic treatment choices. X-GEN’s expanding product line offers a broad range of dosage forms including injectables, anti-infective solutions, oral solids, and inhalants. For further information about X-GEN Pharmaceuticals, call (866) 390-4411, or visit the web-site at www.x-gen.us.
X-GEN Pharmaceuticals, Inc. is proud to be a certified Women Owned Business Enterprise